NewsFOX 13 Tampa BayAugust 27, 2026Hillsborough
FDA approves Rasonque for advanced pancreatic cancer treatment
The FDA has granted expedited approval to the drug daraxonrasib, branded as Rasonque, for patients with advanced pancreatic cancer. Clinical trials showed the daily pill nearly doubled median survival time compared to chemotherapy for patients whose cancer had stopped responding to prior treatments.
Read the full story at FOX 13 Tampa BayWhy It Matters
Patients with advanced pancreatic cancer now have access to a new treatment option priced at approximately $39,800 per month that has demonstrated increased survival rates in clinical studies.
Key Facts
Each fact below is taken from the article. Click one to see the exact passage.
Who's Mentioned
personAndrew Coveler“Doctor at Fred Hutch Cancer Center who commented on the approval.”organizationFood and Drug Administration“The federal agency that approved the new drug.”personBen Sasse“Former U.S. Senator who publicly shared his experience taking the drug.”organizationRevolution Medicines“The company selling the drug under the brand name Rasonque.”organizationAmerican Cancer Society“Provided statistics on pancreatic cancer diagnosis and mortality.”